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A B S T R A C T
We investigated ADHD symptoms and life outcomes in adulthood and their association with childhood ADHD
and subthreshold symptoms in a prospectively followed cohort with perinatal risks. We identiﬁed participants
with childhood ADHD (cADHD, n=37), subthreshold symptoms deﬁned as attention problems (cAP, n=64),
and no ADHD or cAP (Non-cAP, n=217). We compared the groups and a control group with no perinatal risks
(n=64) on self-reported ADHD symptoms, executive dysfunction, and life outcomes in adulthood. At age 40,
21.6% of the cADHD, 6.3% of the cAP, 6.0% of the Non-cAP group, and 1.6% of the controls reached a screener
cutoﬀ for possible ADHD. The cADHD group had lower educational level, more ADHD symptoms and executive
dysfunction, and higher rates of drug use than the other groups. Childhood ADHD associated with perinatal risks
persists into midlife whereas childhood subthreshold ADHD symptoms in this cohort were not associated with
negative outcomes in adulthood.
1. Introduction
Attention deﬁcit/hyperactivity disorder (ADHD) has an estimated
prevalence of 2–5% in adulthood (Kooij et al., 2010; Matte et al., 2015).
The reports of persistence of ADHD from childhood to adulthood vary
extensively with estimates ranging between 4% and 77% depending on
the length of the follow-up and the deﬁnition of both childhood and
adulthood ADHD (Faraone et al., 2006a; Sibley et al., 2016). Most
longitudinal studies on ADHD only extend into adolescence or early
adulthood, and prospective longitudinal studies continuing to the third
and fourth decade are rare. The few studies extending beyond young
adulthood have mostly consisted of clinic-referred boys (Klein et al.,
2012; Satterﬁeld et al., 2007). The persistence estimates for studies
with a follow-up period of minimum 20 years range between 6% and
32% (Sibley et al., 2016). A recent cohort study over four decades found
childhood-onset ADHD to continue into midlife in only 5% of cases
(Moﬃtt et al., 2015).
Symptoms of ADHD form a continuum (Marcus and Barry, 2011).
Focusing on subjects with an established diagnose thus excludes those
with symptoms below a diagnostic threshold from research and clinical
scope (Faraone and Biederman, 2016). Although ADHD symptoms
usually decline with age (Biederman et al., 2000; Faraone et al., 2006a),
the individual course of symptoms varies throughout childhood and
adulthood (Karam et al., 2017; Larsson et al., 2011). An individual
might thus fulﬁll the diagnostic criteria at one point during their life
and remain at a subthreshold level at another. Importantly, comorbid
psychiatric disorders, such as substance use disorder and conduct dis-
order (Shankman et al., 2009), and adverse psychosocial outcomes
(Norén Selinus et al., 2016) frequently associated with ADHD
(Kooij et al., 2010), have also been found in adolescents and adults with
previous subthreshold ADHD symptoms.
Adverse life outcomes and functional impairment associated with
ADHD in adulthood are well established (Barkley et al., 2008;
Biederman et al., 2006; Shaw et al., 2012). ADHD is linked to lower
educational and occupational level (Biederman et al., 2012; Shaw et al.,
2012), and higher rates of unemployment (Biederman et al., 2006).
Moreover, the risk for comorbid psychiatric disorders is elevated
(Kooij et al., 2010), including a high probability for substance use
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disorder (Klein et al., 2012) and mood disorders (Biederman et al.,
2012). Importantly, adults with a history of childhood ADHD exhibit
adverse life outcomes and high levels of impairment even if ADHD
symptoms are no longer severe (Caye et al., 2016; Moﬃtt et al., 2015).
Dysfunction in executive functions has been proposed to be central in
adult ADHD and partly explain these adverse outcomes (Adler et al.,
2017; Barkley et al., 2008; Barkley and Fischer, 2011).
The long-term eﬀects of early adverse events at birth on ADHD
symptoms have been scarcely studied. In a recent review, low birth
weight and preterm birth posed the greatest risk among perinatal
complications for developing ADHD by age twelve (Serati et al., 2017).
A longitudinal study to adolescence found complications in pregnancy
and labor to be associated with ADHD symptoms throughout the follow-
up period, with the association decreasing by age (Brinksma et al.,
2017). Also, adults with ADHD symptoms have been reported to have a
history of low birth weight or preterm birth more often than people
with no ADHD symptoms (Halmøy et al., 2012; Strang-Karlsson et al.,
2008).
This study examines ADHD symptom development and life out-
comes in a cohort with perinatal risks followed prospectively from
birth. Our primary aim was to investigate whether ADHD symptoms
and executive dysfunction were elevated at age 40 in subjects with
childhood ADHD or subthreshold symptoms. Our secondary aim was to
examine life outcomes including education, occupation, psychiatric
symptoms, and drug and alcohol use in relation to childhood ADHD and
subthreshold symptoms. We also evaluated medical factors that may




The participants are from a longitudinal research project (Perinatal
Adverse Events and Special Trends in Cognitive Trajectory, PLASTIC-
ITY) (Hokkanen et al., 2013). The prospective birth cohort (1196 in-
fants) consists of individuals born in one maternity hospital in Helsinki
in 1971–1974 (Michelsson et al., 1978). The participants had one or
several pre-deﬁned perinatal risks, such as low birth weight (see Table
S1). Subjects who had severe disabilities (cerebral palsy, severe sensory
deﬁcits, intellectual disability), or died before the age of 5 were ex-
cluded (see Fig. 1) (Launes et al., 2014). A control group of 164 sin-
gletons with no perinatal risks born in the same hospital was also fol-
lowed from childhood. For the latest follow-up at 40 years, risk cohort
members and controls whose addresses were found in the Population
Registry Center of Finland (n=1061) were invited via mail, of whom
607 responded. We included subjects who had participated in both
childhood follow-ups at ages 5 and 9 (risk cohort n=318, control
group n=64). Brain MRI scans (see Table S2) were used to exclude
participants due to traumatic brain injuries or strokes. Visual assess-
ment of the images was performed by a specialist in neuroradiology
(RV), who was blinded to all clinical parameters. Participation is illu-
strated in Fig. 1. The project was approved by Ethical Review Board of
the Helsinki and Uusimaa hospital district (number 147/13/3/00/
2013). Written informed consent was gathered from all participants.
2.2. Deﬁning childhood symptom groups
The risk cohort participants were grouped into three diﬀerent ca-
tegories: childhood ADHD (cADHD n=37), attention problems (cAP;
n=64) and no ADHD or attention problems (Non-cAP, n=217). The
cADHD group had a disorder identiﬁed earlier (Tervo et al., 2017),
whereas in the cAP group symptoms were not severe enough to warrant
an ADHD diagnosis. The cAP group had symptoms of either inattention
or hyperactivity/ impulsivity or both. The control group (n=64) had
no perinatal risks, cADHD, or cAP. The childhood symptom grouping
was based on multiple study observations, informant reports, and as-
sessments at 5 and 9 years of age (see Tables S3-S6). ADHD was not a
diagnosis in use at the time of the childhood follow-up and was diag-
nosed retrospectively by the ﬁrst principal investigator of the project
(KM) using all the information described above (Hokkanen et al.,
2013). Subthreshold symptoms were identiﬁed with a norm-based ap-
proach (Barkley et al., 2008; Sibley et al., 2016), in which scores of the
controls were used to create threshold percentiles. The complete pro-
tocol for childhood symptom assessments is described in the supple-
mentary materials.
2.3. Measures
Childhood socioeconomic status (SES) was deﬁned as the highest
median status of mother and father recorded in childhood assessments
(0, 5, and 9 years). Four classes, based on occupational level, were
originally used, but the two lowest categories were merged due to small
numbers. Level 1 represents the highest SES class. Information on
mother's education was collected in the latest follow-up and divided
into three levels: basic, secondary and tertiary. Current information on
ADHD symptoms and life outcomes was gathered through a ques-
tionnaire ﬁlled online or on paper, and during on-site neurological and
neuropsychological evaluations in 2014–2016.
Current subjective ADHD symptoms were estimated with the World
Health Organization Adult ADHD Self-Report Screening Scale, ASRS-
v1.1 (Kessler et al., 2005). The ASRS screener measures inattention and
hyperactivity according to DSM-IV criteria (American Psychiatric
Association, 2000) with six questions. The wording of the questions was
modiﬁed to ﬁt the broader questionnaire. The general score of the ASRS
(range 0–24) was analyzed and participants were grouped according to
a cutoﬀ point (scores at or above 14) (Kessler et al., 2007). In our
sample, a cutoﬀ point of two standard deviations above the control
group mean, a cutoﬀ point suggested in the literature (Barkley et al.,
2008; Sibley et al., 2016), coincided with the recommended cutoﬀ score
of 14. Scores for hyperactivity and inattention were summed to assess
ADHD symptom domains. There were 20 missing values in the screener,
which were imputed with the average of the corresponding childhood
group.
Executive dysfunction was assessed with the Behavior Rating
Inventory - Adult version (BRIEF-A) (Roth et al., 2005). BRIEF-A self-
report results in a General Executive Composite (GEC) and two indexes,
Behavioral Regulation Index (BRI), and Metacognition Index (MI). The
MI consists of scales Initiate, Working Memory, Plan/ Organize, Task
Monitor, and Organization of Materials. The BRI is consists of scales
Inhibit, Shift, Emotional Control, and Self-Monitor. The BRI assesses
regulation of behavior and emotions, and the MI ability to plan and
monitor activities. The raw score was compared to normative data in
the manual and transformed into T-scores, with a threshold of T≥ 65
for elevated score (Roth et al., 2005).
Data on the participants’ education, occupation, mental health,
smoking, as well as alcohol and drug use were gathered with the
questionnaire. Highest educational degree was classiﬁed into three le-
vels: Basic (9 years), secondary (10–12 years) and tertiary education
(13+ years). Grade average from comprehensive school (around age
16) was collected. The lowest possible grade is 4 and highest 10.
Occupational status was recorded as currently employed or un-
employed. Future work ability was assessed by asking the participants
to estimate the number of years they would be able to continue
working. Psychiatric symptoms were assessed using the short version of
the Depression Anxiety Stress Scales (DASS-21) (Lovibond and
Lovibond, 1995), which was translated and modiﬁed by transformation
into a 5 item Likert scale. Alcohol use was assessed with the Finnish
version of the Alcohol Use Disorders Test (AUDIT) (World Health
Organization, 2001). Life-time drug use was asked separately for can-
nabis and other illicit drugs but combined for the analysis.
All subjects underwent a semi-structured medical and
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Fig. 1. Flow chart of the participants. †Died after childhood follow-ups.
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socioeconomic history interview by a neurologist with 25 years of
clinical experience (JL), who was not blinded to the birth data. We had
access to purchases of reimbursed prescription medicines provided by
the Social Insurance Institution of Finland, ICD-8 and ICD-9 codes of
discharge from public hospitals since 1980 and from 2002 onwards also
from outpatient care, provided by the National Institute for Health and
Welfare THL. All medical data were systematically reviewed by JL and
a list of adulthood concomitant conditions was compiled. Conditions
related to mental health, sleep disorders, and neurological conditions
were reviewed in evaluating possible underlying factors for ADHD
symptoms in adulthood.
2.4. Statistical analyses
Statistical analyses were conducted using IBM SPSS software, ver-
sion 24. Means and standard deviations were calculated for all con-
tinuous variables and percentages for categorical variables. Chi-square
test was used to compare proportions in contingency tables.
Logarithmic transformations were applied when necessary to make
distributions of variables less skewed and were used to conduct uni-
variate ANOVA analyses. Kruskall-Wallis analysis of variance, Mann-
Whitney-U two sample tests, and rank analysis of covariance
(Quade, 1967) were used when assumptions for parametric tests were
not met. Logistic regression analysis was used to predict outcome and
calculate odds ratios for ASRS screener cutoﬀ group. Holm-Bonferroni
corrections were applied to all pairwise analyses due to multiple com-
parisons. Eﬀect sizes were estimated with Cramer's V for contingency
tables and partial eta squared for continuous variables.
3. Results
Demographic characteristics and test statistics for the childhood
symptom groups are shown in Table 1. The groups diﬀered on gender,
age, and childhood SES. Gender and childhood SES were used as
covariates in all analyses of outcome measures. Age was not included as
a covariate because the range in all groups was narrow (39 to 45 years)
and the eﬀect size was small.
The participating risk cohort and controls (n=382) were compared
to non-participants (cohort 300, controls 58, total n=358). Fewer men
participated in the follow-up [46.9% vs. 59.5%; χ²(1),= 11.85,
p= .001, V=0.13]. There were no diﬀerences in birth risks (all p
values > 0.3), or childhood SES between the participants and non-
participants (p= .21). The participants and non-participants diﬀered
on childhood group status (χ²(3),= 12.18, p= .007). There were more
participants than non-participants in the Non-cAP group [56.8% vs
45.8%, χ²(1)= 8.95, p= .017, V=0.11]. In the cAP group, fewer
subjects participated in the follow-up [16.8% vs. 24.9%, χ²(1)= 7.40,
p= .033, V=0.10].
The childhood symptom groups diﬀered on level of education, grade
average, subjective future work ability, and drug use (Table 1). The
groups also diﬀered on ASRS total and hyperactive scores (Table 2). The
groups diﬀered on reaching a cutoﬀ score on ASRS (χ²(3),= 15.83,
p= .001, V=0.20, Fig. 2). In pairwise comparisons, a higher propor-
tion of the cADHD group reached the cutoﬀ than of the Non-cAP,
(p= .007) and control (p= .004) groups. In total, 53.8% (14 out of 26)
of those reaching the ASRS cutoﬀ did not belong to the cADHD or cAP
groups and hence did not have ADHD or subthreshold symptoms in
childhood (Fig. 2). The BRIEF-A GEC and Index scores, as well as some
Scale scores diﬀered between the childhood symptom groups (Table 2).
The groups diﬀered on reaching a cutoﬀ for elevated symptoms on the
BRIEF-A GEC [χ²(3),= 13.21, p= .004, V=0.19], see Fig. 2. More
participants in the cADHD group exceeded the cutoﬀ than in the Non-
cAP (p= .026) and control groups (p= .006). The bivariate correlation
for BRIEF-A GEC T score and ASRS total score was 0.65, p < .001.
Current medications were drugs primarily indicated for treating
arterial hypertension (n=39), depression (n=37), psychosis (n=7),
and asthma (n=25). Antidepressive and antipsychotic medications
were also used for several oﬀ-label indications, e.g. sleep disturbance,
Table 1
Demographic characteristics and life outcomes at 40 years in childhood ADHD and attention problem groups.
Childhood group
cADHD cAP Non-cAP Controls
(1) (2) (3) (4)
N=37 N=64 N=217 N=64
Characteristic n (%) or M±SD n (%) or M±SD n (%) or M±SD n (%) or M±SD χ²/ F p V/ η2 Pairwise comparison
Sex (male) 24 (64.9) 35 (54.7) 93 (42.9) 27 (42.2) 8.35 .039 .15
Age at follow-up 42.1 ± 1.27 41.8 ± 1.24 42.3 ± 1.27 41.6 ± 1.27 12.92 .005 .026 3 > 4*
SES in childhood 19.28 .004 .16
Level 1 5 (13.5) 17 (26.6) 47 (21.7) 26 (40.6) 4 > 1,3*
Level 2 11 (29.7) 11 (17.2) 64 (29.5) 20 (31.3)
Level 3 21 (56.8) 36 (56.3) 106 (48.8) 18 (28.1) 2 > 4⁎⁎; 1,3 > 4*
Mother's education (n=365) 3.69 .72 .07
Basic 10 (29.4) 23 (37.7) 69 (33.2) 15 (24.2)
Secondary 20 (58.8) 28 (45.9) 106 (51.0) 36 (58.1)
Tertiary 4 (11.8) 10 (16.4) 33 (15.9) 11 (17.7)
Occupational Status (employed) 32 (86.5) 58 (90.6) 204 (94.0) 61 (95.3) 3.79 .29 .10
Subjective work ability (years) 19.77± 4.67 20.89± 4.69 21.27± 4.35 22.47± 3.64 3.31 .020 .03 4 > 1*
Education 53.45 < 0.001 .26
Basic 14 (37.8) 6 (9.4) 11 (5.1) 1 (1.6) 1 > 3,4⁎⁎⁎; 1 > 2⁎⁎
Secondary 16 (43.2) 37 (57.8) 118 (54.4) 30 (46.9)
Tertiary 7 (18.9) 21 (32.8) 88 (40.6) 33 (51.6) 4 > 1⁎⁎
Grade average† 6.58± 1.10 7.50± 1.12 7.76±1.24 8.10±1.31 37.44 < 0.001 .09 3,4 > 1⁎⁎⁎; 2 > 1⁎⁎
Smoking (yes) 10 (27.0) 19 (29.7) 38 (17.5) 9 (14.1) 7.18 .07 .14
Drug use 10 (27.0) 4 (6.3) 19 (8.8) 5 (7.8) 13.70 .003 .15 1 > 3⁎⁎; 1 > 2,4*
Alcohol use (Audit) 8.17± 5.64 6.13± 3.95 6.53±4.63 5.94±2.78 0.97 .41 .01
DASS-21 total score 24.88± 15.93 18.74± 14.03 17.56± 12.35 17.98± 12.54 2.39 .07 .02
cADHD, childhood ADHD; cAP, childhood attention problem; Non-cAP, no childhood ADHD or attention problems; SES, socioeconomic status; Audit, Alcohol Use
Disorders Test; DASS, Depression Anxiety Stress Scales.
† Grade average in comprehensive school.
⁎ p < .05.
⁎⁎ p < .01.
⁎⁎⁎ p < .001.
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migraine and pain. Additionally, 37 subjects had medications for en-
docrine disorders, rheumatoid arthritis, Crohn's disease and epilepsy.
There was no diﬀerence between the study groups in current medica-
tion for depression [χ²(3)= 1.04, p= .79, Mean rank for cADHD
198.8, cAP 193.9, Non-cAP 190.6, controls 187.9]. None of the parti-
cipants had medication for ADHD either currently or in childhood.
Adulthood concomitant conditions related to mental health, sleep
disorders, and neurological conditions were found in 10/26 (38.5%)
participants exceeding the cutoﬀ on ASRS and in 62/356 participants
(17.4%) in the remaining cohort [χ²(1)= 7.02, p= .008, V=0.14].
Conditions were equally distributed across the childhood symptom
groups [χ²(3)= 4.37, p= .22, V=0.11]. In those exceeding the ASRS
cutoﬀ, two conditions were found in the cADHD, three in the cAP, four
in the Non-cAP, and one in the control group. Higher DASS-21 score
and belonging to the cADHD group predicted reaching the ASRS cutoﬀ
in logistic regression analysis (Table 3). The full model was signiﬁcant
compared to a model with constant only [χ²(12)= 68.80, p < .001].
4. Discussion
In this prospective cohort study of 382 participants over four dec-
ades we found childhood ADHD to be associated with higher rates of
Table 2
ADHD and executive functions symptom scores at 40.
Childhood group
cADHD cAP Non-cAP Controls
(1) (2) (3) (4)
N=37 N=64 N=217 N=64
Variable M±SD n (%) M±SD n (%) M±SD n (%) M±SD n (%) F p η2 Pairwise comparison
ASRS Tot 9.43± 5.06 6.30±4.51 6.20± 4.09 6.69± 3.49 5.45 .001 .041 1 > 3***; 1 > 4**
ASRS Hyp 3.16± 2.24 1.98±1.79 1.69± 1.72 2.0 ± 1.83 5.37 .001 .041 1 > 3***
ASRS Inat 6.27± 4.03 4.53±3.29 4.52± 3.15 4.69± 2.70 2.49 .06 .019
BRIEF-A GEC 56.89±10.99 51.33± 9.20 50.74± 9.45 49.42±7.53 4.67 .003 .036 1 > 3,4**; 1 > 2*
BRIEF-A BRI 56.16±12.25 49.91± 10.68 49.93± 9.61 48.09±8.37 4.94 .002 .038 1 > 3,4**; 1 > 2*
Inhibit 54.84±8.74 49.55± 9.62 48.46± 8.03 46.77±6.67 7.11 < 0.001 .054 1 > 3,4***; 1 > 2**
Shift 55.78±12.83 49.70± 9.82 51.34± 10.11 50.03±10.43 2.84 .038 .022 1 > 2*
EC 54.35±12.48 50.41± 10.79 50.72± 10.48 49.28±9.69 2.23 .09 .017
Self-M 55.43±11.59 49.56± 11.02 48.69± 9.22 47.27±8.0 4.75 .003 .037 1 > 3,4**; 1 > 2*
BRIEF-A MI 56.76±9.88 52.39± 8.72 51.43± 9.45 50.70±7.49 3.44 .017 .027 1 > 3,4*
Initiate 56.65±12.80 53.70± 10.46 52.24± 10.29 52.16±8.66 1.23 .3 .01
WM 61.54±11.84 54.86± 12.04 54.73± 10.70 53.44±9.45 4.54 .004 .035 1 > 2,3,4***
Plan 55.54±8.72 50.31± 8.26 49.59± 8.61 48.95±8.38 5.07 .002 .039 1 > 3,4**; 1 > 2*
TM 56.11±9.09 52.84± 8.22 52.76± 9.60 52.17±8.48 1.53 .21 .012
OM 50.51±10.53 50.16± 10.10 48.62± 9.75 48.05±8.91 0.74 .53 .006
cADHD, childhood ADHD; cAP, childhood attention problem; Non-cAP, no childhood ADHD or attention problems; ASRS, Adult ADHD Self-Report Screening Scale;
ASRS Tot, ASRS total score; ASRS Hyp, ASRS hyperactive score, ASRS Inat, ASRS inattention score; GEC, general executive composite; BRI, behavioral regulation
index; MI, metacognitive index; EC, emotional control; Self-M, self-monitor; WM, working memory; TM, task monitor; OM, organization of materials; * p< .05, ** p
< .01, *** p < .001. All BRIEF-A descriptive data are presented as T-scores.
Fig. 2. Percentage of subjects reaching a cutoﬀ on measures of ADHD symptoms and executive dysfunction in childhood groups with 95% conﬁdence intervals.
cADHD, childhood ADHD; cAP, childhood attention problem; Non-cAP, no childhood ADHD or attention problems; ASRS, Adult ADHD Self-Report Screening Scale,
score≥ 14; cADHD n=8, cAP n=4, Non-cAP n=13, Control n=1. BRIEF-A, Behavior Rating Inventory of Executive Functions, Adult, GEC T score≥ 65: cADHD
n=9, cAP n=5, Non-cAP n=19, Control n=2.
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ADHD symptoms, executive dysfunction, and educational under-
achievement at age 40 compared to those who had subthreshold or no
symptoms in childhood. Childhood subthreshold symptoms were not
associated with elevated symptoms or negative outcomes in adulthood.
In addition to reporting more ADHD symptoms at age 40 than the
other groups, one ﬁfth of the cADHD group reached a cutoﬀ for possible
ADHD. ADHD symptoms appear to persist in adulthood, as a follow-up
of the same cohort at age 30 also showed higher rates of ADHD
symptoms in the cADHD group compared to controls (Tervo et al.,
2017). Previous estimates of ADHD persistence from longitudinal stu-
dies with individuals aged 30 or older (Sibley et al., 2016) have yielded
comparable results, suggesting that severe ADHD symptoms continue
beyond young adulthood among those with childhood ADHD. Still,
most individuals with cADHD (78%) in our study no longer had ele-
vated symptoms. This estimate is highly similar to results reported in
two other longitudinal studies with adults over the age 30, where
74–78% of subjects with childhood ADHD did not fulﬁll the diagnostic
criteria in adulthood (Klein et al., 2012; Mannuzza et al., 2011). The
estimate in the present study is lower compared to another longitudinal
cohort study, where 95% of subjects with childhood ADHD did not have
ADHD in adulthood (Moﬃtt et al., 2015). Even though diﬀerent as-
sessment methods and deﬁnitions of ADHD were used in these and the
present study, the percentage of symptom-free individuals is of the
same magnitude. Thus, while there is a group of adults with childhood
ADHD who still have evident ADHD symptoms, for the majority, these
symptoms appear to alleviate by midlife.
Previous longitudinal studies have found hyperactive symptoms to
decrease with age more than inattentive symptoms (Biederman et al.,
2000). Diﬀering from these results, the cADHD group reported more
hyperactive symptoms than the Non-cAP group. Hyperactivity may
have declined with age in our cohort, but we were unable to estimate
this as the same measure was not used in childhood. The ASRS screener
contains only two questions on hyperactivity and might thus not cap-
ture all symptoms of hyperactivity. Nonetheless, group-level diﬀerences
suggest that hyperactivity, or the feeling of restlessness, continues to
identify those with childhood ADHD in midlife. In a study of ADHD
symptom trajectories in adulthood, it was more common for hyper-
activity to increase over time than impulsivity or inattention
(Karam et al., 2017). These results signal the importance of assessing
hyperactivity in adults, despite the general trend of these symptoms
decreasing with age (Biederman et al., 2000).
Childhood ADHD was associated with greater self-reported
executive dysfunction in adulthood. Executive functioning is linked to
adult ADHD and suggested to be a better predictor of the disorder than
symptoms in diagnostic criteria only (Adler et al., 2017; Barkley et al.,
2008; Kessler et al., 2011). Behavioral regulation, particularly in-
hibitory control and monitoring one's behavior in social situations, was
poorer in the cADHD group than in the remaining cohort and controls.
Deﬁcits in these skills could result in risky and impulsive behavior, as
well as diﬃculties in maintaining social relationships due to lack of
understanding how one's behavior aﬀects others. The capacity to
maintain and hold information in mind, and the ability to plan and
organize future events were also aﬀected, which are skills highly
needed in educational and work settings. In another longitudinal study,
Biederman and colleagues (Biederman et al., 2012) found similar re-
sults: Scores on most BRIEF-A scales were impaired in men who had
ADHD as boys compared to controls. Our results add to the evidence of
executive dysfunction being a key element in ADHD, and highlight the
importance of evaluating executive functions if adult ADHD is sus-
pected (Adler et al., 2017; Barkley et al., 2008).
As expected on the basis of literature and previous studies of our
cohort (Barkley et al., 2008; Klein et al., 2012; Michelsson and
Lindahl, 1987; Tervo et al., 2017), educational underachievement was
prominent in the cADHD group; one third had completed only basic
education by the age of 40. Educational underachievement was ac-
companied with poor academic performance as the cADHD group re-
ported the lowest grade average among the groups. Our results indicate
that those with childhood ADHD do not continue their studies at a later
age, but permanently remain on a low educational track.
We found no diﬀerences in the employment status or psychiatric
symptoms across the study groups, but life-time use of drugs was higher
in the cADHD group. This result supports previous evidence of an as-
sociation between childhood ADHD and later substance use (Caye et al.,
2016; Klein et al., 2012). As for employment status, it is only a snapshot
of the situation at one given time. When we asked the participants to
estimate their future work ability, the cADHD group estimated their
ability as worse than the controls. This is in line with other studies
indicating occupational impairment among children with ADHD fol-
lowed to adulthood (Barkley and Fischer, 2011; Klein et al., 2012). Lack
of signiﬁcant diﬀerences between the groups on other outcome mea-
sures may partly be explained by attrition bias. Our study group likely
represents high functioning individuals as participating in the follow-up
required commitment (Launes et al., 2014).
Overall, our results suggest that varied perinatal risks per se are not
associated with negative life outcomes, executive problems, or ADHD
symptoms in midlife as individuals in the perinatal risk group without
childhood ADHD did not diﬀer from controls. However, we cannot
exclude the mediating eﬀect of childhood ADHD associated with peri-
natal risk as we did not have a group with childhood ADHD without
perinatal risks. Previous research has showed certain pre- and perinatal
risk factors to be associated with adult ADHD (Halmøy et al., 2012).
Investigating perinatal risks separately might reveal diﬀerences in as-
sociated ADHD symptom trajectories but could not be done in our study
due to small numbers in risk groups.
In the present cohort, subthreshold ADHD symptoms were not as-
sociated with high rates of ADHD symptoms or negative outcomes in
midlife. Similar to our ﬁndings, a longitudinal study found subthreshold
ADHD not to predict the full syndrome over the course of 15 years
(Shankman et al., 2009). Also, in a cross-sectional study individuals
with subthreshold ADHD were less impaired and had fewer psychiatric
disorders than those with a full disorder (Faraone et al., 2006b).
However, in a recent meta-analysis subthreshold ADHD was asso-
ciated with functional impairment similar to that of the full disorder
(Kirova et al., 2019). Even though the subthreshold group in this study
did not diﬀer from the other groups on negative outcomes, there was a
trend for the cAP group to exhibit higher rates of smoking and psy-
chiatric symptoms and lower rates of employment and tertiary educa-
tion. Because the subthreshold group was small and we compared three
Table 3
Predictors for reaching a cutoﬀ on the ASRS screener.
Predictor B SE Adjusted OR 95% CI p
Sex (male) 0.25 0.59 1.29 0.41–4.08 .67
Childhood SES†
Level 2 0.69 0.75 1.99 0.46–8.70 .36
Level 3 0.36 0.81 1.43 0.30–6.95 .66
Education‡
Basic −1.08 0.99 0.34 0.05–2.34 .27
Secondary −0.10 0.63 0.91 0.27–3.11 .88
Smoking (yes) 1.01 0.58 2.75 0.88–8.62 .08
Audit score −0.05 0.05 0.95 0.86–1.05 .32
Drug use (yes) −0.49 0.83 0.62 0.12–3.13 .56
DASS-21 0.12 0.02 1.13 1.08–1.18 < 0.001
Childhood group
cADHD 3.25 1.26 25.81 2.20–302.47 .010
cAP 1.37 1.27 3.94 0.32–47.79 .28
Non-cAP 1.90 1.15 6.71 0.70–64.22 .10
SES, socioeconomic status; Audit, Alcohol Use Disorders Test; DASS-21,
Depression Anxiety Stress Scales; cADHD, childhood ADHD; cAP, childhood
attention problem; Non-cAP, no childhood ADHD or attention problems; CI,
conﬁdence interval.
† compared to Level 1.
‡ compared to Tertiary.
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groups and performed multiple analyses, statistical analyses might not
have reached signiﬁcance even if group-level diﬀerences were present.
Also, most evidence for negative outcomes in subthreshold ADHD come
from children and young adults (Biederman et al., 2018; Kirova et al.,
2019). Our subthreshold group might have had more problems at a
younger age but do not manifest these negative outcomes at a group
level later in adulthood, possibly due to catching up with peers later in
development. Supporting this view, subthreshold ADHD did not to
develop into the full syndrome in any participants in a longitudinal
study over 15 years with several follow-ups in adulthood, implying that
the core symptoms of ADHD do not tend to increase after adolescence
(Shankman et al., 2009).
Childhood subthreshold symptoms have been proposed to underlie
adult ADHD without known history of childhood ADHD
(Asherson et al., 2016; Faraone and Biederman, 2016; Moﬃtt et al.,
2015), but based on the current ﬁndings alternative hypotheses should
be considered. Half of those exceeding the screener cutoﬀ for ADHD did
not have ADHD or subthreshold symptoms in childhood. As these in-
dividuals did not exhibit ADHD symptoms in several assessment si-
tuations or informant-reports in childhood, the cause for signiﬁcant
ADHD-like symptoms at age 40 is unlikely to be childhood ADHD. It is
more likely that scoring high on the ADHD screener is due to other
factors, namely psychiatric symptoms, causing attentional problems
(Sibley et al., 2018). This seems to be the case in our cohort, as self-
reported psychiatric symptoms were a signiﬁcant predictor for ex-
ceeding the cutoﬀ. Also, ﬁve out of 14 participants without childhood
ADHD/ AP exceeding the cutoﬀ had concomitant conditions that could
explain the high screener score. However, psychiatric disorders have a
high degree of genetic correlation, implying that having a psychiatric
disorder does not exclude having ADHD as well (The Brainstorm
Consortium, 2018). Thus, the possibility of few individuals presenting
an onset of ADHD later in childhood or during adolescence or adult-
hood cannot be ruled out.
The greatest strengths of the study are the long prospective follow-
up period and similarity in early environmental and perinatal risk
factors between the study groups. Comparisons between childhood
ADHD symptom groups and controls enables better evaluation of the
impact of childhood ADHD and subthreshold symptoms on outcomes in
adulthood. Another strength is that the life-time medical history of the
subjects is known in detail. One of the limitations of the study may be
that ADHD was not a diagnostic disorder at the time of childhood
follow-up. Therefore, the classiﬁcation had to be performed retro-
spectively. However, the diagnosis is based on extensive data from in-
vestigators and informants collected especially for recognizing beha-
vioral symptoms. The ADHD screener measure of this study is widely
used (Kessler et al., 2007), but consists of only 6 questions and does not
cover all features of ADHD symptoms listed in DSM-IV diagnostic cri-
teria (American Psychiatric Association, 2000). However, the six-
question screener has been shown to outperform the full 18-question
scale (Kessler et al., 2005), and the scoring method used in the present
study has a good predictive value for clinical diagnosis (Kessler et al.,
2007). In a longitudinal study, attrition bias cannot be avoided. While
the cADHD group was similarly represented in participants and non-
participants, fewer members of the cAP group, and fewer men, parti-
cipated in the follow-up than in the childhood assessments. Despite
these limitations, our results suggest that childhood ADHD, but not
subthreshold levels of ADHD symptoms, are associated with evident
ADHD symptoms and poor educational outcome at age 40 in a perinatal
risk population.
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